Images

Filter by

Figure 5 A Clear Example of Second degree Advanced IAB
Figure 5: A Clear Example of Second-degree Advanced IAB
Figure 4 This is an Example of Partial Interatrial Block without Left Atrial Enlargement
Figure 4: This is an Example of Partial Interatrial Block without Left Atrial Enlargement
Figure 3 Adapted from Experimental Bachmann’s Bundle Block Waldo et al 1971
Figure 3: Adapted from Experimental Bachmann’s Bundle Block (Waldo et al. 1971)
Figure 2 A and B P wave Morphology in V1 and P loop in a Case of Isolated Partial Interatrial Block B and Associated with Left Atrial Enlargement A
Figure 2: (A and B) P wave Morphology in V1 and P loop in a Case of Isolated Partial Interatrial Block (B) and Associated with Left Atrial Enlargement (A)
Figure 1 Left Scheme of Atrial Activation in a Normal P wave A in Presence of Partial IAB B and of Advanced IAB C Right Characteristics of the P loop and P wave in Each Case
Figure 1: Left: Scheme of Atrial Activation in a Normal P wave (A), in Presence of Partial IAB (B), and of Advanced IAB (C). Right: Characteristics of the P loop and P wave in Each Case
Table 1 Prevalence of IAB in a Cohort of Global Population of 70–80 Years and 100 Years
Table 1 : Prevalence of IAB in a Cohort of Global Population of 70–80 Years and 100 Years
Mechanism of Diuretic Resistance
Mechanism of Diuretic Resistance
Schematic of a Dose‐response Curve of Loop Diuretics in Heart Failure Patients Compared with Controls
Schematic of a Dose‐response Curve of Loop Diuretics in Heart Failure Patients Compared with Controls
Table 1 Summary of Diuretic Drugs used in Heart Failure
Table 1: Summary of Diuretic Drugs used in Heart Failure
ESC Guidelines for the Management of LVSD100
ESC Guidelines for the Management of LVSD100
Algorithm for the Management of Cardiotoxicity in Patients Treated with Anthracyclines8
Algorithm for the Management of Cardiotoxicity in Patients Treated with Anthracyclines8
Algorithm for Continuation and Discontinuation of Trastuzumab Based on LVEF Assessments8
Algorithm for Continuation and Discontinuation of Trastuzumab Based on LVEF Assessments8